Tokyo, Jan. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060269) titled 'Immune Function Evaluation Test for Levilactobacillus brevis subsp. coagulans FERM BP-4693 (Labre)' on Jan. 15.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Double blind -all involved are blinded
Control - Placebo
Primary Sponsor:
Institute - Clinical Creative Co., Ltd.
Condition:
Condition - healthy person
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The primary endpoint will be the intergroup difference in the cumulative number of Good Health Days (GHD) during the intervention period in adults aged 20...